Nanostructure-based platforms-current prospective in ophthalmic drug delivery

Indian Journal of Ophthalmology

Volumn 62, Issue 7, 2014, Pages 768-772

  Sharma, Rakesh ^a   Yassin, Alaa Eldeen ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Hydrophillic nanogels; nanosponges; ophthalmic drug delivery; solid lipid nanoparticles

Indexed keywords

EYE DROPS; NANOPARTICLE;

DRUG DELIVERY SYSTEM; HUMAN; RETINAL DISEASES;

DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; OPHTHALMIC SOLUTIONS; RETINAL DISEASES;

EID: 84906244762     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.138301     Document Type: Review

References (46)

1. Eljarrat?Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010;27:530-43.
2. Dayle H, Geroski, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthamol Vis Sci 2000;4:961-4.
3. Paulsen F. Anatomy and physiology of efferent tear ducts. Ophthalmologe 2008;105:339-45.
4. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595-639.
5. Lang JC. Ocular drug delivery: Conventional ocular formulations. Adv Drug Deliv Rev 1995;16:39-43.
6. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006;58:1136-63.
7. Kunou N, Ogura Y, Yasukawa T, Kimura H, Miyamoto H, Honda Y, et al. Long?term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000;68:263-71.
8. Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F. Non?ionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. Sciences et techniques pharmaceutiques, Pharma Sciences 1996;6:94-8.
9. Eshar D, Wyre NR, Schoster JV. Use of collagen shields for treatment of chronic bilateral corneal ulcers in a pet rabbit. J Small Anim Pract 2011;52:380-3.
10. Grass JM, Robinson JR. Relationship of chemical structure to corneal penetration and influence of low viscosity solution on ocular bioavailability. J Pharm Sci 1984;73:1021-7.
11. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Concept and development of ophthalmic pseudo?lattices triggered by pH. Int J Pharm 1991;77:211-9.
12. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm 1982;12:147-52.
13. Qi H, Chen W, Huang C, Li L, Chen C, Li W, et al. Development of a poloxamer analogs/carbopol?based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007;337:178-87.
14. Yin H, Gong CY, Shi S, Liu X, Wei Y, Qian Z. Toxicity Evaluation of Biodegradable and Thermosensitive PEG?PCL?PEG Hydrogel as a Potential in situ sustained ophthalmic drug delivery system. J Biomed Mater Res B Appl Biomater 2010;92:129-37.
15. ElKamel AH. In vitro and in vivo evaluation of pluronic F 127?based ocular delivery system for timolol maleate. Int J Pharm 2002;241:47-55
16. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008;60:1638-49.
17. Zatloukal Z, Sklubalová Z. Sterilized ophthalmic hydrogels with hydroxypropyl methyl cellulose: Determination and mathematical treatment of flow properties. Pharm Dev Technol 2007;12:55-60.
18. Burgalassi S, Chetoni P, Saettone MF. Hydrogels for ocular delivery of pilocarpine: Preliminary evaluation in rabbits of the influence of viscosity and of drug solubility. Eur J Pharm Biopharm 1996;42:385-92.
19. Bell CL, Peppas NA. Biomedical membranes from hydrogels and interpolymer complexes. Adv Polym Sci 1995;122:125-75.
20. Coviello T, Maricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Control Release 2007;119:5-24
21. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002;43:3-12.
22. Tayel SA, El-Narawi MA, Tadros MI, Abd?Elsalam WH. Promising ion?sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: Design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm 2013;443:293-305.
23. Kesavan K, Kant S, Singh PN, Pandit JK. Effect of hydroxypropyl?β? cyclodextrin on the ocular bioavailability of dexamethasone from a pH?induced mucoadhesive hydrogel. Curr Eye Res 2011;36:918-29.
24. Ortega MD, Lorenzo CA, Concheiro A, Loftsson T. Dexamethasone eye drops containing χ?cyclodextrin?based nanogels. Int J Pharm 2013;441:507-15.
25. Yassin AE, Bekairy AA, Katheri AA, Sharma RK. Anticancer?loaded solid lipid Nanoparticles: High Potential Advancement in chemotherapy. Dig J Nanomater Biostruct 2013;8:905-16.
26. Li R, Jiang S, Liu D, Bi X, Wang F, Zhang Q, et al. A potential new therapeutic system for glaucoma: Solid lipid nanoparticles containing methazolamide. J Microencapsul 2011;28:134-41.
27. Kalam AM, Sultana Y, Ali A, Aqil M, Mishra A, Aljuffali A, et al. Part I: Development and optimization of solid?lipid nanoparticles using Box?Behnken statistical design for ocular delivery of gatifloxacin. J Biomed Mater Res A 2013;101:1813-27.
28. Kalam AM, Sultana Y, Ali A, Aqil M, Mishra A, Aljuffali A, et al. Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J Biomed Mater Res A 2013;101:1828-36.
29. Seyfoddin A, Al?Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013;39:508-19.
30. Hippalgaonkar K, Adelli GR, Repka MA, Majumdar S. Indomethacin?Loaded Solid Lipid Nanoparticles for ocular delivery: Development, characterization, and In vitro evaluation. J Ocul Pharmacol Ther 2013;29:216-28.
31. Trotta F, Cavalli R. Characterization and application of new hyper?cross?linked cyclodextrins, Compos. Interfaces 2009;16:39-48.
32. Cavalli R, Trotta F, Tumiatti W. Cyclodextrinbased nanosponges for drug delivery. J Incl Phenom Macrocycl Chem 2006;56:209-13.
33. Swaminathan S, Vavia PR, Trotta F, Torne S. Formulation of betacyclodextrin based nanosponges of itraconazole. J Incl Phenom Macrocycl Chem 2007;57:89-94.
34. Shende P, Deshmukh K, Trotta F, Caldera F. Novel cyclodextrin nanosponges for delivery of calcium in hyperphosphatemia. Int J Pharm 2013;456:95-100.
35. Renuka S, Kamla P. Polymeric Nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation. Pharm Dev Technol 2011;16:367-76.
36. Jenny A, Merima P, Alberto F, Francesco T. Role of β cyclodextrin nanosponges in polypropylene photooxidation. Carbohydr Polym 2011;86:127-35.
37. Lala R, Throat A, Gargote C. Current trends in βcyclodextrin based drug delivery systems. Int J Res Ayur Pharm 2011;2:1520-6.
38. Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: Formulation design, Physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotechnol 2013;9:998-1007.
39. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm 2007;338:21-6.
40. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F 127gpoly (acrylic acid) copolymer as insitu gelling vehicle for ophthalmic drug delivery system. Int J Pharm 2008;350:247-56.
41. Shen J, Gan L, Zhu C, Zhang X, Dong Y. Noval NSAIDS Ophthalmic formulation: Flubiprofenaxetil emulsion with low irritancy and improved antiinflammation effect. Int J Pharm 2011;412:115-22.
42. Attama AA, Reichl S, MullerGoymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307-13.
43. Verstraelen S, Jacob A, De Wever B, Vanparys P. Improvement of the Bovine corneal Opacity and Permeability (BCOP) assay as an in vitro alternative to the Draize rabbit eye irritation test. Toxicol In Vitro 2013;27:1298-311.
44. Tian BC, Zhang W J, Xu HM, Hao MX, Liu YB, Yang XG, et al. Further investigation of nanostructured lipid carriers as an ocular delivery system: In vivo transcorneal mechanism and in vivo release study. Colloids Surf B Biointerfaces 2013;102:251-6.
45. Kaluzhny Y, Kandá rová H, Hayden P, Kubilus J, d'Argembeau Thornton L, Klausner M, Development of the EpiOcularTM Eye Irritation Test for Hazard Identification and labeling of eye irritating chemicals in response to the requirments of the EU Cosmetics Directive and Reach legislation. Altern Lab Anim 2011;39:339-64.
46. Kolle SN, Kandarova H, Wareing B, Van Ravenzwaay B, Landsiedel R. Inhouse validation of the EpiOcular™ eye irritation test and its combination with the bovine corneal opacity and permeability test for the assessment of ocular irritation. Altern Lab Anim 2011;39:365-87.-baba ^^King Saud Bin Abdulaziz University for health sciences-baba-info The author would like to acknowledge the library facilities provided by King Saud Bin Abdulaziz University for health sciences, Riyadh, Kingdom of Saudi Arabia, for collection of literature